SuperworthCastle Biosciences CSTL
- Market cap
- $1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $357.3M
- +3% on a year ago
- Net margin
- −5.4%
- Free cash flow yield
- −0.0%
Castle Biosciences trades at 2.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $357.3M over the last twelve months, up 3% on a year earlier with a −5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $61.5M+66% | $66.1M+73% | $73M+74% | $87M+74% | $85.8M+40% | $86.3M+31% | $88M+21% | $86.2M−1% | $83M−3% | $87M+1% | $83.7M−5% | $103.5M+20% | |
| Cost of revenue | $11.3M+28% | $12.4M+31% | $13.9M+37% | $14.5M+31% | $15.6M+38% | $16.2M+30% | $16.4M+18% | $17.6M+21% | $18.7M+20% | $18.3M+13% | $20.5M+25% | $23.7M+35% |
| Gross profit | $50.2M+78% | $53.7M+86% | $59.1M+86% | $72.5M+86% | $70.2M+40% | $70.1M+31% | $71.6M+21% | $68.6M−5% | $64.3M−8% | $68.7M−2% | $63.1M−12% | $79.8M+17% |
| R&D | $12.9M+19% | $13M+15% | $13.8M−4% | $14.1M+6% | $12.3M−5% | $11.8M−9% | $12.6M−9% | $12.8M−10% | $13M+5% | $13.5M+15% | $14.4M+15% | $14.5M+14% |
| SG&A | $44.6M+22% | $44.1M+15% | $48.5M+4% | $51.1M+14% | $50.5M+13% | $50M+13% | $58.6M+21% | $58.1M+14% | $55.9M+11% | $56.7M+14% | $64.9M+11% | $66.1M+14% |
| −$9.6M−55% | −$5.7M−75% | −$5.5M−83% | $5M | $5.1M | $4M | −$27.9M+411% | −$4.3M | −$6.8M | −$3.8M | −$18.4M−34% | −$3.1M−28% | |
| Interest expense | $2K−67% | $2K−50% | $14K+250% | $270K+8900% | $201K+9950% | $92K+4500% | $17K+21% | $21K−92% | $24K−88% | $24K−74% | $134K+688% | $193K+819% |
| Pre-tax income | −$6.9M−66% | −$2.5M−88% | −$2.5M−92% | $7.9M | $8.3M | $7.9M | −$26.3M+956% | −$143K | −$386K | −$2.7M | −$14.4M−45% | −$1.7M+1082% |
| $32K | $39K−32% | $45K+221% | −$1M | $6M+18691% | −$1.7M | −$423K | −$4.7M+351% | $115K−98% | −$382K−78% | $109K | $370K | |
| Net income | −$6.9M−66% | −$2.6M−88% | −$2.5M−91% | $8.9M | $2.3M | $9.6M | −$25.8M+920% | $4.5M−49% | −$501K | −$2.3M | −$14.5M−44% | −$2.1M |
| −$0.26−66% | −$0.10−87% | −$0.09−92% | $0.31 | $0.08 | $0.31 | −$0.90+900% | $0.15−52% | −$0.02 | −$0.08 | −$0.49−46% | −$0.07 | |
| 26.8M+2% | 27M+2% | 27.5M+3% | 28.7M+8% | 29.4M+10% | 30.5M+13% | 28.6M+4% | 29.5M+3% | 29.1M−1% | 29.3M−4% | 29.9M+5% | 30.4M+3% |
Cost of revenue: Q1 FY18: 6 months less the 3 months printed beside them.
Gross profit: 21 periods, Q2 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY18 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences | $1B | n/m | 143× | 2.8× | +3% | −5.4% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | 3.8× | +1% | 8.6% | |
| Peer median | $5.1B | 44.8× | 35.1× | 6.9× | +17% | 10.6% |
More on Castle Biosciences
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .